Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Ligand Pharmaceuticals's total debt was $1.13B at Sep 30, 2026. For fiscal 2015 it was $205.37M, up 4.8% from the year before. The highest annual figure on record is $205.37M in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $205.37M | +4.8% |
| FY2014 | Dec 31, 2014 | $195.91M | – |
| FY2013 | Dec 31, 2013 | $0 | -100.0% |
| FY2012 | Dec 31, 2012 | $13.44M | -33.7% |
| FY2011 | Dec 31, 2011 | $20.29M | – |
| FY2010 | Dec 31, 2010 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.13B | – |
See a number that looks wrong?